Search results
Sanofi reports 1Q revenue increase, as sales of vaccines, Dupixent rise
WFMZ Eastern Pennsylvania and Western New Jersey· 2 weeks agoSanofi, a pharmaceutical company with Monroe County operations, reported a 2.4% gain in...
Sanofi (SNY) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 2 weeks agoAs one of the leading medicines in immunology respiratory is a core disease area for Dupixent, well ahead of any of the competing -- of any other...
Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 6 days agoAn increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided...
Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
Zacks via Yahoo Finance· 2 weeks agoDupixent Dupixent generated sales of €2.84 billion in the quarter, up 24.9% year over year. Sales of...
Regeneron’s stock rallies as pipeline prospects outweigh earnings miss
Market Watch· 4 days agoThe revenue shortfall was partly due to a decline in sales of the company’s blockbuster eye drug...
RSV vaccine boosts Monroe County's Sanofi Pasteur
WFMZ Eastern Pennsylvania and Western New Jersey· 2 weeks agoSanofi, a pharmaceutical company with Monroe County operations, reported a 2.4% gain in first-quarter revenue on Thursday, as sales of vaccines and the...
Sanofi profit slips on generic competition and currency effects
Reuters via Yahoo Finance· 2 weeks ago(Reuters) -Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap...
AstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge
Investor's Business Daily· 2 weeks agoSales also fell 2.4% to $11.67 billion, but topped FactSet-polled analysts' consensus call for...
Sanofi to report earnings first-quarter earnings Thursday
WFMZ Eastern Pennsylvania and Western New Jersey· 2 weeks agoParis-based Sanofi is the parent company of vaccine maker Sanofi Pasteur in Pocono Township. The...
Health Care Roundup: Market Talk
The Wall Street Journal· 2 weeks agoAstraZeneca’s growth drivers were its key drugs Farxiga, lung cancer drug Tagrisso and autoimmune disease drug Soliris, which offset the slightly weaker...